First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

Please provide your email address to receive an email when new articles are posted on . The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — Acalabrutinib alone and in combination with obinutuzumab improved PFS compared with obinutuzumab and ...

Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the ...

Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus ...

Implementing routine assessment of patient-reported outcomes in cancer care.